Swedish drug developer Karolinska Development has appointed current board member Klaus Wilgenbus as chief executive on an interim basis, following the departure of Torbjörn Bjerke from the position. 30 September 2014
Inflammation, oncology and biodefense biopharma company Soligenix has announced the appointment of Rasappa Arumugham as vice president of biopharmaceutical development. 23 September 2014
Dimension Therapeutics, a US gene therapy company focused on rare diseases, has appointed Annalisa Jenkins as chief executive, who succeeds interim chief executive Thomas Beck. 17 September 2014
US-based Neurotrope, developers of diagnostic and therapeutic technologies for the treatment of neurodegenerative diseases, has announced the appointment of co-chairmen Charles Ramat and Paul Freiman as co-chief executives on an interim basis. 21 July 2014
UK-based biotech company Oxford BioTherapeutics, focusing on antibody-drug conjugates in the treatment of cancer, has announced the appointment of Eugen Leo as head of clinical development. 11 July 2014
Biotechnology firm Retrogenix has announces the appointment of Matthew Britz as North American Business Development Director with immediate effect. 23 June 2014
US biotech firm Dendreon revealed last evening that John Johnson plans to step down as president and chief executive officer for personal reasons. 10 June 2014
UK-based monoclonal antibody biopharmaceutical company Kymab has announced the appointment of Steve Arkinstall as Chief Scientific Officer and Nigel Clark as Vice President and Head of Business Development. 3 June 2014
US-based biopharmaceutical company Nektar Therapeutics (Nasdaq: NKTR) has announced that Ivan Gergel will serve as the Company's new Senior Vice President, Drug Development & Chief Medical Officer effective immediately. 19 May 2014
US biotech firm Amgen has announced the appointment of Steven Galson to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19. 14 May 2014
UK-based biopharmaceutical company Ario Pharma has announced the appointment of Professor Peter Barnes and Professor Wisia Wedzicha to its Scientific Advisory Board with immediate effect. 12 May 2014
US-based Eleven Biotherapeutics (Nasdaq: EBIO), a clinical-stage biopharmaceutical company developing protein therapeutics to treat eye diseases, has announced the appointment of Gary Sternberg as Executive Vice President of Corporate and Business Development. 8 May 2014
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024